儿童生长贴联合重组人生长激素治疗特发性矮小症的疗效
|
摘要
目的探讨儿童生长贴联合重组人生长激素对特发性矮小症的治疗效果。方法回顾性分析2016年2月～2017年2月我科因特发性矮小症就诊的患儿45例;按治疗方法分为对照组、观察组1、观察组2各15例,对照组为拒绝一切药物治疗者,观察组1为采用儿童生长贴治疗的患儿;观察组2为采用生长贴联合重组人生长激素治疗的患儿,疗程均为12个月。比较身高增长值、遗传身高、预测成年身高。结果对照组、观察组1和观察组2比较,身高增长值分别为(3.87±1.25)cm、(7.93±1.53)cm、(10.20±1.97)cm,差异有显著性(F=59.48,P<0.01);遗传身高分别为(156.80±4.94)cm、(156.07±3.97)cm、(156.13±4.58)cm,差异无显著性(F=0.12,P>0.05);成年预测身高分别为(155.73±3.31)cm、(164.80±5.24)cm、(167.87±5.68)cm,差异有显著性(F=25.35,P<0.01)。结论儿童生长贴联合重组人生长激素治疗特发性矮小症可显著增加患儿身高增长值,提高其成年身高预测值。
Objective To investigate the therapeutic effect of children's growth patch combined with recombinant human growth hormone on idiopathic short stature. Methods A retrospective analysis of 45 children patients with idiopathic short stature from February 2016 to February 2017 was carried out, according to the treatment method, they were divided into the control group, the observation group 1 and the observation group 2, with 15 cases in each group. The control group was those who rejected all medications. The observation group 1 was those who were given children's growth patch; the observation group 2 was those who were given growth patch combined with recombinant human growth hormone therapy. The treatment lasted for 12 months. The height growth, genetic height, and predicted adult height were compared. Results The control group, the observation group 1 and the observation group 2 were compared,and the height growth values were(3.87±1.25) cm,(7.93±1.53) cm, and(10.20±1.97) cm, respectively, and the difference was significant(F=59.48, P<0.01); the genetic heights were(156.80±4.94) cm,(156.07±3.97) cm,(156.13±4.58) cm, respectively, and the difference was not significant(F=0.12, P>0.05); the predicted adult heights were(155.73±3.31) cm,(164.80±5.24) cm, and(167.87±5.68) cm, respectively, and the difference was significant(F=25.35, P<0.01). Conclusion Children's growth patch combined with recombinant human growth hormone in the treatment of idiopathic short stature can significantly increase the height growth value and increase the predicted value of adult height.
Objective To investigate the therapeutic effect of children's growth patch combined with recombinant human growth hormone on idiopathic short stature. Methods A retrospective analysis of 45 children patients with idiopathic short stature from February 2016 to February 2017 was carried out, according to the treatment method, they were divided into the control group, the observation group 1 and the observation group 2, with 15 cases in each group. The control group was those who rejected all medications. The observation group 1 was those who were given children's growth patch; the observation group 2 was those who were given growth patch combined with recombinant human growth hormone therapy. The treatment lasted for 12 months. The height growth, genetic height, and predicted adult height were compared. Results The control group, the observation group 1 and the observation group 2 were compared,and the height growth values were(3.87±1.25) cm,(7.93±1.53) cm, and(10.20±1.97) cm, respectively, and the difference was significant(F=59.48, P<0.01); the genetic heights were(156.80±4.94) cm,(156.07±3.97) cm,(156.13±4.58) cm, respectively, and the difference was not significant(F=0.12, P>0.05); the predicted adult heights were(155.73±3.31) cm,(164.80±5.24) cm, and(167.87±5.68) cm, respectively, and the difference was significant(F=25.35, P<0.01). Conclusion Children's growth patch combined with recombinant human growth hormone in the treatment of idiopathic short stature can significantly increase the height growth value and increase the predicted value of adult height.
引文
[1]班博.特发性矮小症的诊断与治疗[J].济宁医学院学报,2017,40(2):77-92.
[2]吴央,刘燕玲.儿童特发性矮小症治疗进展[J].儿科药学杂志,2015,21(11):61-64.
[3]许乔雯,叶进.特发性矮小症中西医治疗进展[J].山东中医药大学学报,2015,39(6):569-572.
[4]彭艳,张崇建,王英,等.聚乙二醇重组生长激素治疗特发性矮小症儿童效果及对血清p53及p21waf/cip1表达的影响[J].中国儿童保健杂志,2018,26(6):587-593.
[5]中华医学会儿科学会内分泌遗传代谢学组.矮身材儿童诊治指南[J].中华儿科杂志,2008,46(6):428-430.
[6]黄爱娣,李金华,吴潜珍,等.特发性矮小患儿的心理状态及护理对策[J].中国医药导报,2015,12(20):137-140.
[7]朱新宇,陈晶.重组人生长激素治疗特发性矮小患儿的临床研究[J].中国临床药理学杂志,2017,33(10):884-887.
[8]潘嘉严.骨龄和遗传身高对重组人生长激素治疗生长激素缺乏症患儿疗效的影响[J].实用儿科临床杂志,2009,24(14):1117-1118.
[9]卢一丽,金佳蕙,单小鸥.建立新的可预测成年终身高及青春期进程的模型及其在特发性中枢性性早熟女童中的应用[J].中国现代医生,2018,56(4):98-104.
[10]倪佳,辛颖.儿童特发性矮小的诊治进展[J].中国中西医结合儿科学,2015,7(3):199-202.
[11]杨万岭,班博.特发性矮小遗传学研究及展望[J].济宁医学院学报,2018,41(2):77-86.
[12]陈凌华,赵慧,张素珍,等.矮小症儿童主观生活质量和社会适应能力的研究[J].中国儿童保健杂志,2016,24(12):1271-1273.
[13]于萍,朱惠娟,潘慧.生长激素-胰岛素样生长因子1轴相关单基因缺陷性矮小症的研究进展[J].中国卫生检验杂志,2015,25(12):2054-2061.
[14]李静,杨晓丽,高爱梅.特发性矮小患儿IGFBP-3 mRNA表达及基因外显子突变的研究[J].山西医科大学学报,2018,49(2):174-177.
[15]蒋红宇,黄春香.重组人生长激素治疗特发性矮小症35例临床疗效分析[J].儿科药学杂志,2014,20(3):31-33.
[16]俞建,时毓民.矮小症的中医临床研究与展望[J].中国中西医结合儿科学,2015,7(3):193-195.
[17]陈聪明,詹杰,蓝俊才,等.陈荣焜辨治矮小症经验集粹[J].中医药通报,2018,17(2):19-23.
[18]张佳娟,叶进.叶进从小儿脾虚质论治矮小症经验[J].浙江中医药大学学报,2017,41(1):72-74.
[19]孙艳艳,汪永红,封玉琳.中医调治脾肝肾在治疗矮小症中的应用[J].中国中西医结合儿科学,2015,7(3):213-215.
[20]宋鹏,夏桂选.中医治疗矮小症临床文献分析[J].中国中西医结合儿科学,2015,7(4):323-325.
[21]刘建忠,王丽君,林连美,等.扶阳罐配合跑台运动对肾虚矮小症雄性大鼠生长发育相关因子的影响[J].湖北中医杂志,2016,38(3):14-17.
[2]吴央,刘燕玲.儿童特发性矮小症治疗进展[J].儿科药学杂志,2015,21(11):61-64.
[3]许乔雯,叶进.特发性矮小症中西医治疗进展[J].山东中医药大学学报,2015,39(6):569-572.
[4]彭艳,张崇建,王英,等.聚乙二醇重组生长激素治疗特发性矮小症儿童效果及对血清p53及p21waf/cip1表达的影响[J].中国儿童保健杂志,2018,26(6):587-593.
[5]中华医学会儿科学会内分泌遗传代谢学组.矮身材儿童诊治指南[J].中华儿科杂志,2008,46(6):428-430.
[6]黄爱娣,李金华,吴潜珍,等.特发性矮小患儿的心理状态及护理对策[J].中国医药导报,2015,12(20):137-140.
[7]朱新宇,陈晶.重组人生长激素治疗特发性矮小患儿的临床研究[J].中国临床药理学杂志,2017,33(10):884-887.
[8]潘嘉严.骨龄和遗传身高对重组人生长激素治疗生长激素缺乏症患儿疗效的影响[J].实用儿科临床杂志,2009,24(14):1117-1118.
[9]卢一丽,金佳蕙,单小鸥.建立新的可预测成年终身高及青春期进程的模型及其在特发性中枢性性早熟女童中的应用[J].中国现代医生,2018,56(4):98-104.
[10]倪佳,辛颖.儿童特发性矮小的诊治进展[J].中国中西医结合儿科学,2015,7(3):199-202.
[11]杨万岭,班博.特发性矮小遗传学研究及展望[J].济宁医学院学报,2018,41(2):77-86.
[12]陈凌华,赵慧,张素珍,等.矮小症儿童主观生活质量和社会适应能力的研究[J].中国儿童保健杂志,2016,24(12):1271-1273.
[13]于萍,朱惠娟,潘慧.生长激素-胰岛素样生长因子1轴相关单基因缺陷性矮小症的研究进展[J].中国卫生检验杂志,2015,25(12):2054-2061.
[14]李静,杨晓丽,高爱梅.特发性矮小患儿IGFBP-3 mRNA表达及基因外显子突变的研究[J].山西医科大学学报,2018,49(2):174-177.
[15]蒋红宇,黄春香.重组人生长激素治疗特发性矮小症35例临床疗效分析[J].儿科药学杂志,2014,20(3):31-33.
[16]俞建,时毓民.矮小症的中医临床研究与展望[J].中国中西医结合儿科学,2015,7(3):193-195.
[17]陈聪明,詹杰,蓝俊才,等.陈荣焜辨治矮小症经验集粹[J].中医药通报,2018,17(2):19-23.
[18]张佳娟,叶进.叶进从小儿脾虚质论治矮小症经验[J].浙江中医药大学学报,2017,41(1):72-74.
[19]孙艳艳,汪永红,封玉琳.中医调治脾肝肾在治疗矮小症中的应用[J].中国中西医结合儿科学,2015,7(3):213-215.
[20]宋鹏,夏桂选.中医治疗矮小症临床文献分析[J].中国中西医结合儿科学,2015,7(4):323-325.
[21]刘建忠,王丽君,林连美,等.扶阳罐配合跑台运动对肾虚矮小症雄性大鼠生长发育相关因子的影响[J].湖北中医杂志,2016,38(3):14-17.